Patents by Inventor Raymond D. Skwierczynski

Raymond D. Skwierczynski has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11872206
    Abstract: The subject matter disclosed herein relates to rofecoxib, also known as TRM-201 or RXB-201, its method of manufacture, and use. In certain aspects, the highly pure or substantially pure rofecoxib as provided herein has a favorable purity profile and is the active ingredient in a pharmaceutical composition that is administered to treat or prevent a number of conditions, including pain associated with a condition caused by a bleeding disorder.
    Type: Grant
    Filed: July 1, 2022
    Date of Patent: January 16, 2024
    Assignee: Tremeau Pharmaceuticals, Inc.
    Inventors: Raymond D. Skwierczynski, Bradford C. Sippy, Jean-Marie Schneider, Simon H. Drouin, Charles Guerin
  • Publication number: 20230265111
    Abstract: The present invention provides novel compounds useful as proteasome inhibitors. The invention also provides pharmaceutical compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various diseases.
    Type: Application
    Filed: May 3, 2023
    Publication date: August 24, 2023
    Inventors: Eric L. Elliott, Abu J. Ferdous, Michael J. Kaufman, Sonja A. Komar-Lay, Debra L. Mazaik, Quentin J. McCubbin, Phuong M. Nguyen, Vaithianathan Palaniappan, Raymond D. Skwierczynski, Nobel T. Truong, Csanad M. Varga, Peter N. Zawaneh
  • Patent number: 11617735
    Abstract: The subject matter disclosed herein relates to rofecoxib, also known as TRM-201 or RXB-201, its method of manufacture, and use. In certain aspects, the highly pure or substantially pure rofecoxib as provided herein has a favorable purity profile and is the active ingredient in a pharmaceutical composition that is administered to treat or prevent a number of conditions, including pain associated with a condition caused by a bleeding disorder.
    Type: Grant
    Filed: June 28, 2022
    Date of Patent: April 4, 2023
    Assignee: Tremeau Pharmaceuticals, Inc.
    Inventors: Raymond D. Skwierczynski, Bradford C. Sippy, Jean-Marie Schneider, Simon H. Drouin, Charles Guerin
  • Patent number: 11576890
    Abstract: The subject matter disclosed herein relates to rofecoxib, also known as TRM-201 or RXB-201, its method of manufacture, and use. In certain aspects, the highly pure or substantially pure rofecoxib as provided herein has a favorable purity profile and is the active ingredient in a pharmaceutical composition that is administered to treat or prevent a number of conditions, including pain associated with a condition caused by a bleeding disorder.
    Type: Grant
    Filed: February 26, 2021
    Date of Patent: February 14, 2023
    Assignee: Tremeau Pharmaceuticals, Inc.
    Inventors: Raymond D. Skwierczynski, Bradford C. Sippy, Jean-Marie Schneider, Simon H. Drouin, Charles Guerin
  • Patent number: 11559509
    Abstract: The subject matter disclosed herein relates to rofecoxib, also known as TRM-201 or RXB-201, its method of manufacture, and use. In certain aspects, the highly pure or substantially pure rofecoxib as provided herein has a favorable purity profile and is the active ingredient in a pharmaceutical composition that is administered to treat or prevent a number of conditions, including pain associated with a condition caused by a bleeding disorder.
    Type: Grant
    Filed: June 28, 2022
    Date of Patent: January 24, 2023
    Assignee: Tremeau Pharmaceuticals, Inc.
    Inventors: Raymond D. Skwierczynski, Bradford C. Sippy, Jean-Marie Schneider, Simon H. Drouin, Charles Guerin
  • Publication number: 20220409575
    Abstract: The subject matter disclosed herein relates to novel doses and dosage forms of rofecoxib having a therapeutic benefit.
    Type: Application
    Filed: June 30, 2022
    Publication date: December 29, 2022
    Applicant: Tremeau Pharmaceuticals, Inc.
    Inventors: Bradford C. Sippy, Raymond D. Skwierczynski, Travis E. Helm
  • Publication number: 20220409568
    Abstract: The subject matter disclosed herein relates to rofecoxib, also known as TRM-201 or RXB-201, its method of manufacture, and use. In certain aspects, the highly pure or substantially pure rofecoxib as provided herein has a favorable purity profile and is the active ingredient in a pharmaceutical composition that is administered to treat or prevent a number of conditions, including pain associated with a condition caused by a bleeding disorder.
    Type: Application
    Filed: June 28, 2022
    Publication date: December 29, 2022
    Applicant: Tremeau Pharmaceuticals, Inc.
    Inventors: Raymond D. Skwierczynski, Bradford C. Sippy, Jean-Marie Schneider, Simon H. Drouin, Charles Guerin
  • Publication number: 20220378736
    Abstract: The subject matter disclosed herein relates to rofecoxib, also known as TRM-201 or RXB-201, its method of manufacture, and use. In certain aspects, the highly pure or substantially pure rofecoxib as provided herein has a favorable purity profile and is the active ingredient in a pharmaceutical composition that is administered to treat or prevent a number of conditions, including pain associated with a condition caused by a bleeding disorder.
    Type: Application
    Filed: July 1, 2022
    Publication date: December 1, 2022
    Applicant: Tremeau Pharmaceuticals, Inc.
    Inventors: Raymond D. Skwierczynski, Bradford C. Sippy, Jean-Marie Schneider, Simon H. Drouin, Charles Guerin
  • Publication number: 20220362206
    Abstract: The subject matter disclosed herein relates to rofecoxib, also known as TRM-201 or RXB-201, its method of manufacture, and use. In certain aspects, the highly pure or substantially pure rofecoxib as provided herein has a favorable purity profile and is the active ingredient in a pharmaceutical composition that is administered to treat or prevent a number of conditions, including pain associated with a condition caused by a bleeding disorder.
    Type: Application
    Filed: June 28, 2022
    Publication date: November 17, 2022
    Applicant: Tremeau Pharmaceuticals, Inc.
    Inventors: Raymond D. Skwierczynski, Bradford C. Sippy, Jean-Marie Schneider, Simon H. Drouin, Charles Guerin
  • Patent number: 11485746
    Abstract: The present invention provides novel compounds useful as proteasome inhibitors. The invention also provides pharmaceutical compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various diseases.
    Type: Grant
    Filed: April 24, 2020
    Date of Patent: November 1, 2022
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Eric L. Elliott, Abu J. Ferdous, Michael J. Kaufman, Sonja A. Komar-Lay, Debra L. Mazaik, Quentin J. Mccubbin, Phuong M. Nguyen, Vaithianathan Palaniappan, Raymond D. Skwierczynski, Nobel T. Truong, Csanad M. Varga, Peter N. Zawaneh
  • Publication number: 20220125773
    Abstract: Described herein are compositions and methods for treatment with aqueous formulations of water insoluble COX-2 inhibitors and a solubilizing agent.
    Type: Application
    Filed: October 27, 2021
    Publication date: April 28, 2022
    Inventors: Bradford C. SIPPY, Raymond D. SKWIERCZYNSKI
  • Publication number: 20220047542
    Abstract: The subject matter disclosed herein relates to novel doses and dosage forms of rofecoxib having a therapeutic benefit.
    Type: Application
    Filed: October 28, 2021
    Publication date: February 17, 2022
    Applicant: Tremeau Pharmaceuticals, Inc.
    Inventors: Bradford C. Sippy, Raymond D. Skwierczynski, Travis E. Helm
  • Publication number: 20220009948
    Abstract: The present invention provides novel compounds useful as proteasome inhibitors. The invention also provides pharmaceutical compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various diseases.
    Type: Application
    Filed: September 23, 2021
    Publication date: January 13, 2022
    Inventors: Eric L. Elliott, Abu J. Ferdous, Michael J. Kaufman, Sonja A. Komar-Lay, Debra L. Mazaik, Quentin J. Mccubbin, Phuong M. Nguyen, Vaithianathan Palaniappan, Raymond D. Skwierczynski, Nobel T. Truong, Csanad M. Varga, Peter N. Zawaneh
  • Publication number: 20210236455
    Abstract: The subject matter disclosed herein relates to rofecoxib, also known as TRM-201 or RXB-201, its method of manufacture, and use. In certain aspects, the highly pure or substantially pure rofecoxib as provided herein has a favorable purity profile and is the active ingredient in a pharmaceutical composition that is administered to treat or prevent a number of conditions, including pain associated with a condition caused by a bleeding disorder.
    Type: Application
    Filed: February 26, 2021
    Publication date: August 5, 2021
    Applicant: Tremeau Pharmaceuticals, Inc.
    Inventors: Raymond D. Skwierczynski, Bradford C. Sippy, Jean-Marie Schneider, Simon H. Drouin, Charles Guerin
  • Patent number: 11053214
    Abstract: The present invention provides new pseudo-polymorphs of the hemisuccinate salt of 2,4,6-trifluoro-N-[6-(1-methyl-piperidine-4-carbonyl)-pyridin-2-yl]-benzamide which are useful in pharmaceutical compositions, for example, for the treatment and prevention of migraine headache.
    Type: Grant
    Filed: December 5, 2017
    Date of Patent: July 6, 2021
    Assignee: CoLucid Pharmaceuticals, Inc.
    Inventors: Brigida Allieri, Paul Fagan, Emma Sharp, Raymond D. Skwierczynski
  • Publication number: 20210198289
    Abstract: The present invention provides novel compounds useful as proteasome inhibitors. The invention also provides pharmaceutical compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various diseases.
    Type: Application
    Filed: March 11, 2021
    Publication date: July 1, 2021
    Inventors: Eric L. Elliott, Abu J. Ferdous, Michael J. Kaufman, Sonja A. Komar-Lay, Debra L. Mazaik, Quentin J. Mccubbin, Phuong M. Nguyen, Vaithianathan Palaniappan, Raymond D. Skwierczynski, Nobel T. Truong, Csanad M. Varga, Peter N. Zawaneh
  • Publication number: 20210169845
    Abstract: The subject matter disclosed herein relates to novel doses and dosage forms of rofecoxib having a therapeutic benefit.
    Type: Application
    Filed: February 23, 2021
    Publication date: June 10, 2021
    Applicant: Tremeau Pharmaceuticals, Inc.
    Inventors: Bradford C. Sippy, Raymond D. Skwierczynski, Travis E. Helm
  • Publication number: 20210137878
    Abstract: The subject matter disclosed herein relates to novel doses and dosage forms of rofecoxib having a therapeutic benefit.
    Type: Application
    Filed: December 18, 2020
    Publication date: May 13, 2021
    Applicant: Tremeau Pharmaceuticals, Inc.
    Inventors: Bradford C. Sippy, Raymond D. Skwierczynski, Travis E. Helm
  • Patent number: 10987337
    Abstract: The subject matter disclosed herein relates to rofecoxib, also known as TRM-201 or RXB-201, its method of manufacture, and use. In certain aspects, the highly pure or substantially pure rofecoxib as provided herein has a favorable purity profile and is the active ingredient in a pharmaceutical composition that is administered to treat or prevent a number of conditions, including pain associated with a condition caused by a bleeding disorder.
    Type: Grant
    Filed: December 16, 2019
    Date of Patent: April 27, 2021
    Assignee: Tremeau Pharmaceuticals, Inc.
    Inventors: Raymond D. Skwierczynski, Bradford C. Sippy, Jean-Marie Schneider, Simon H. Drouin, Charles Guerin
  • Patent number: 10945992
    Abstract: The subject matter disclosed herein relates to novel doses and dosage forms of rofecoxib having a therapeutic benefit.
    Type: Grant
    Filed: May 5, 2020
    Date of Patent: March 16, 2021
    Assignee: Tremeau Pharmaceuticals, Inc.
    Inventors: Bradford C. Sippy, Raymond D. Skwierczynski, Travis E. Helm